ALKS (Alkermes) Research & Development: $355 Mil (TTM As of Mar. 2026)


ALKS Alkermes PLC ALKS
70 GF Score
Price $53.26
GF Value $31.33
Valuation Significantly Overvalued
! 8 Warning Signs
View Full Analysis

What is Alkermes Research & Development?

Alkermes ALKS +5.57% 70 Research & Development is $355 Mil as of Mar. 2026. GuruFocus rates ALKS with a GF Score™ of 70/100 and a GF Value™ of $31.33 (Significantly Overvalued). The stock has 8 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Alkermes's Research & Development for the three months ended in Mar. 2026 was $103 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was $355 Mil.

Alkermes  (NAS:ALKS) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Alkermes Research & Development Related Terms

Alkermes Research & Development Historical Data

* Premium members only.

The historical data trend for Alkermes's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Alkermes Research & Development Chart

Alkermes Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 290.92 272.70 270.81 245.33 323.96

Alkermes Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 71.82 77.37 81.74 93.04 103.35
ALKS
70GF Score
Alkermes PLC ALKS
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Alkermes Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $355 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $355 Mil mean?
Alkermes (ALKS) has a Research & Development of $355 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Alkermes and its competitors.
Is Alkermes' Research & Development too high?
Alkermes' current Research & Development is $355 Mil. Overall, Alkermes has a GF Score™ of 70/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Alkermes' Research & Development compare to LNTH and HIMS?
Alkermes' Research & Development of $355 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Alkermes and its competitors. Alkermes's current Research & Development is $355 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alkermes stock overvalued right now?
Based on GuruFocus' analysis, Alkermes (ALKS) is currently considered Significantly Overvalued. The stock's GF Value™ is $31.33, compared to a current price of $53.26 — trading 70% above its estimated fair value. The current Research & Development is $355 Mil. Alkermes' overall GF Score™ is 70/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Alkermes (ALKS), the current Research & Development is $355 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Alkermes (ALKS) Overvalued in 2026?

Based on GuruFocus' analysis, Alkermes stock appears to be overvalued. The current stock price of $53.26 is trading 70% above its estimated GF Value™ of $31.33. GuruFocus considers Alkermes to be Significantly Overvalued.

Key valuation signals for ALKS:

  • Research & Development: $355 Mil
  • GF Value™: $31.33 vs. price of $53.26 (70% above fair value)
  • GF Score™: 70/100 with 8 warning signs

No single metric tells the full story. See the ALKS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Alkermes Business Description

Other Exchanges 8AK:Germany
Address 1 Burlington Road, Connaught House, Dublin, IRL, D04 C5Y6
Alkermes PLC is a fully integrated biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in therapeutic areas. The company utilizes several to develop and commercialize products and, in so doing, access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies. It operates in U.S., which derives maximum revenue, Ireland and Rest of the world.
70GF Score

Get the complete analysis for ALKS

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$53.26
Price
$31.33
GF Value